With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure. Kids may have an easier time than adults getting treatment approved, some experts say. Medicaid programs and private insurers have often balked at paying for the pricey drugs for adults, but stricter Medicaid guidelines for kids may make coverage more routine. The two drugs approved for pediat
Friday, April 7, 2017 News Recap Canada Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...
The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing th
Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II clinical trial. The finding suggests that the therapy might be an effective approach to preventing reinfection in such patients. Josh Levitsky, MD, MS, professor of Medicine in the Division of Gastroenterology and Hepatology, was the co...
HealthDay News — For kidney transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 infection, treatment with ledipasvir-sofosbuvir (Harvoni) for 12 or 24 weeks is safe and efficacious, according to a study published online Nov 15 in the Annals of Internal Medicine. Massimo Colombo, MD, from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, and colleagues conducted a randomized phase 2 trial to examine the safety and efficacy
PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Below are the submissions we have made, from
Current Treatments as of August 2017 There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare. Many of the older combinations involve the use of interferon which has many side effects. The list below is of the latest and most effective drugs for treating hepatitis C in Canada. Although there are fewer side effects with the new drugs compared to those of earlier treatments (telaprevir, inte
(NEWSCHANNEL 3) - Michigan Medicaid is now starting to approve coverage of a popular but expensive Hepatitis-C drug.This comes just one month after Newschannel 3 learned that many in Michigan suffering from Hepatitis-C, were being denied Harvoni through the state's Medicaid program, due to the high price.The drug costs about $94,500 for the complete treatment, mostly curing Hepatitis-C."It's been a closed door, it's been frustrating for me and my physician...
SAN FRANCISCO — For patients with hepatitis C who are receiving opioid substitutes, the once-daily single-tablet combination of sofosbuvir plus ledipasvir (Harvoni Gilead Sciences) is well tolerated and effective, according to an analysis of data from the phase 3 ION studies."As long as you anticipate drug interactions, opiate therapy should not prevent treatment," said Nancy Reau, MD, from Rush University Medical Center in Chicago, who presented the findi
– Liver Transplant Patients and Those with Decompensated Cirrhosis Can Now be Treated With 12 Weeks of All-Oral Therapy –FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 16, 2016-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved additional indications for Harvoni® (ledipasvir/sofosbuvir) for use in chronic hepatitis C patients with advanced liver disease. Harvoni in combination with ribavirin (RB